-
Court upholds Lilly's patent for Cymbalta
INDIANAPOLIS — Drug maker Eli Lilly will get at least two more years of patent exclusivity on a drug used to treat depression, anxiety and pain resulting from diabetic neuropathy and fibromyalgia, thanks to a court order issued Wednesday.
The U.S. District Court for the Southern District of Indiana ruled to forbid Wockhardt and other generic drug companies from selling generic versions of Cymbalta (duloxetine hydrochloride) until patent protection expires, which is expected to occur in June 2013.
-
APF expands PainSafe educational initiative with new information, resources
BALTIMORE — The American Pain Foundation on Wednesday launched new information and resources on pain medication safety for acetaminophen and nonsteroidal anti-inflammatory drugs as part of its PainSafe educational initiative.
The new information will be launched with a national public service announcement emphasizing the safe use of pain treatment options, particularly medications containing NSAIDs (aspirin, ibuprofen and naproxen) and acetaminophen (Tylenol and APAP).